Navigation Links
Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
Date:3/13/2009

and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 9,600 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, risks associated with acquisitions and investments, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Covance Purchases Equity Stake in Caprion Proteomics
2. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
3. Covance Decides to Pursue Its Original Preclinical Strategy in China
4. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
5. Covance to Present at The R.W. Baird 2008 Growth Stock Conference
6. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
8. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2007 Financial Results Conference Call
9. Simbionix Increases Product Offerings for OB/GYN Physicians
10. R&D Spending by U.S. Biopharmaceutical Companies Increases 3 Percent in 2008
11. Despite Economic Woes, Physician Compensation Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... develop proprietary medical food, functional food, and dietary supplement products ... , ... North Brunswick, NJ and ... biotechnology company at the crossroads of foods and pharmaceuticals, and ... to announce the signing of a Memorandum of Understanding (MOU) ...
(Date:12/16/2009)... death from roadside bombs to freeway crashes. Traumatic injury, ... to 44, often overwhelms the body,s natural blood-clotting process. ... a team led by Erin Lavik, a new Case ... doctoral student, James P. Bertram, built synthetic platelets that ... work is published in Science Translational Medicine ., ...
(Date:12/16/2009)... solution by swimming , ... ... U.S. Department of Energy’s (DOE) Argonne National Laboratory and Northwestern ... microgears when suspended in a solution, providing insights for design ... gears are a million times more massive than the bacteria,” ...
(Date:12/16/2009)... 16 Sequenom, Inc. (Nasdaq: SQNM ... Buechler and Mr. David Pendarvis to its board ... ) ,, Kenneth F. Buechler, Ph.D., was president, ... From 1988 to 1994, Dr. Buechler was Biosite,s ... Buechler was a senior research scientist for the ...
Breaking Biology Technology:WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities 2WellGen, Inc. and RFI Ingredients to Collaborate on Therapeutic Nutrition Opportunities 3Researchers take the inside route to halt bleeding 2Argonne Scientists Use Bacteria to Power Simple Machines 2Argonne Scientists Use Bacteria to Power Simple Machines 3Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3
... 1,200 new, jobs within 36 months of initiating operations in its second ... ... St. Jude,Medical, Inc. (NYSE: STJ ) today announced plans to expand ... Industrial Park, which will allow the company to increase its,Puerto Rico operations by ...
... Coulter,Inc. (NYSE: BEC ), a leading developer, ... innovate complex biomedical testing,announced today that Charles Slacik, ... will present at the 2007 UBS Global,Life Sciences ... p.m.,(EDT). (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ) The ...
... BIRMINGHAM, Ala., Sept. 19 BioCryst,Pharmaceuticals, Inc. ... findings,from a Phase II study with intramuscular ... for the treatment of seasonal and,life-threatening influenza. ... The study was a randomized, double-blind, placebo-controlled ...
Other Biology Technology:St. Jude Medical to Expand Puerto Rico Operations 2Beckman Coulter to Present at the UBS Global Life Sciences Conference 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 3BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 4BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 5BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 6BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 7
(Date:12/16/2009)... iQor, a global provider of business process ... InfoWorld 100 Awards Top 100 IT project of ... the first submission for iQor. ,, "We are honored ... said Vikas Kapoor, president and CEO of iQor. "TeQ21 ... us to work faster, smarter and with the added ...
(Date:12/16/2009)... BIO-key International, Inc. (OTC Bulletin ... safety and finger-based biometric identification solutions, announced ... a Special Shareholder Meeting held today approved ... Division to Interact911 Mobile Systems Inc. Of ... favor and 1.2% were opposed. ,, (Logo: ...
(Date:12/16/2009)... Va., Dec. 9 CSC (NYSE: ... the American Association for Laboratory Accreditation awarded ... (ISO/IEC) 17025:2005 accreditation to the company,s Test ... Identity Labs located in Fairmont, W.Va. The ... laboratory in the world to achieve this ...
Breaking Biology News(10 mins):iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 1AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 3AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 4AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 5AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 6AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 13582 7US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 1US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 2US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 3US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 4US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 5US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 6US FDA Approves Extavia 28R 29 the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease 4853 7A crystal ball for brain cancer 3F 54598 1A crystal ball for brain cancer 3F 54598 2A crystal ball for brain cancer 3F 54598 3
... AWRE ) today announced that it has amended and ... of comments and a request from the Securities and Exchange ... range of the tender offer to between $2.20 and $2.60 ... share. Aware has also extended the expiration date for the ...
... Improve Application Processing for Passports and Identity CardsFALLS CHURCH, ... ) today announced that the UK Identity and Passport ... responsible for issuing UK passports and ID cards, has ... services contract to upgrade the IPS application and enrollment ...
... 6, 2009 -- Which is a better strategy, ... conventional cropping more profitable than organic farming? Is ... the University of Wisconsin,s College of Agriculture and ... established the Wisconsin Integrated Cropping Systems Trial (WICST) ...
Other Biology News:Aware, Inc. Amends and Extends Dutch Auction Tender Offer 2Aware, Inc. Amends and Extends Dutch Auction Tender Offer 3Aware, Inc. Amends and Extends Dutch Auction Tender Offer 4CSC Awarded $570 Million IT Services Contract by UK Identity and Passport Service 2